PAF-induced bowel necrosis
- 17 Downloads
- 11 Citations
Abstract
Ischemic bowel necrosis in the rat is produced by injecting platelet-activating factor (PAF) intravenously. Since intestinal hypoperfusion is observed after PAF injection, we hypothesize that mesenteric vasoconstriction is the mechanism of bowel injury. We thus studied the effects of vasodilators in this model. We found that: (1) Phenoxybenzamine, prazosin, ICI 198615 (leukotriene antagonist) and PGE1 counteracted the PAF-induced mesenteric flow reduction and ameliorated the bowel injury. However, phenoxybenzamine and prazosin were relatively ineffective in correcting PAF-induced hypotension, showing that bowel injury can be prevented independently of the hypotensive state. (2) Nitroglycerin failed to prevent bowel injury, although it improved the mesenteric blood flow. Thus, in opposition to our initial hypothesis, correction of the mesenteric flow reduction induced by PAF does not always prevent intestinal necrosis. (3) Only phenoxybenzamine, prazosin, ICI 198615, and PGE1 ameliorated PAF-induced hemoconcentration and bowel injury. This suggests a correlation between vascular injury (expressed by “leaky” vessels and the consequent hemoconcentration) and bowel necrosis. (4) Although both nitroglycerin and hydralazine relax smooth muscle, hydralazine seemed to aggravate bowel necrosis. The mechanism remains unclear.
Key Words
PAF (platelet-activating factor) PAF-acether intestinal necrosis splanchnic circulationPreview
Unable to display preview. Download preview PDF.
References
- 1.Benveniste J: PAF-acether, an ether phospholipid with biological activity.In Biological Membranes: Aberrations in Membrane Structure and Function. ML Karnovsky, LC Bolis, (eds). New York, Alan R. Liss, 1988, pp. 73–85.Google Scholar
- 2.Hanahan DJ: Platelet activating factor: A biologically active phosphoglyceride. Annu Rev Biochem 55:483–509, 1986Google Scholar
- 3.Chignard M, LeCouedic JP, Tence M, Vargaftig BB, Benveniste J: The role of Platelet-activating factor in platelet aggregation. Nature 279:799–800, 1979Google Scholar
- 4.O'Flaherty J, Wykle RL, Miller CH, Lewis JC, Waite M, Bass DA, McCall CE, DeChatelet LR: 1-o-alkyl-sn-glyceryl-3-phosphorylcholines. A novel class of neutrophil stimulants. Am J Pathol 103:70–79, 1981Google Scholar
- 5.Dewald B, Baggiolini M: Platelet-activating factor as a stimulus of exocytosis in human neutrophils. Biochim Biophys Acta 888:42–48, 1986Google Scholar
- 6.McManus LM, Hanahan DJ, Demopoulos CA, Pinckard RN: Pathobiology of the intravenous infusion of acetyl glycery ether phosphorylcholine (AGEPC), a synthetic platelet-activating factor (PAF), in the rabbit. J Immunol 124:2919–2924, 1980Google Scholar
- 7.Halonen M, Palmer JD, Lohman C, McManus LM, Pinckard RN: Respiratory and circulatory alterations induced by acetyl glyceryl ether phosphorylcholine. A mediator of IgE anaphylaxis in the rabbit. Am Rev Respir Dis 122:915–924, 1980Google Scholar
- 8.Bessin P, Bonnet J, Apffel D, Soulard C, Desgroux L, Pelas I, Benveniste J: Acute circulatory collapse caused by platelet-activating factor (PAF-acether) in dogs. Eur J Pharmacol 86:403–413, 1983Google Scholar
- 9.Gonzalez-Crussi F, Hsueh W: Experimental model of ischemic bowel necrosis. The role of platelet activating factor and endotoxin. Am J Pathol 112:127–135, 1983Google Scholar
- 10.Hsueh W, Gonzalez-Crussi F, Arroyave JL: Platelet activating factor induced ischemic bowel necrosis. An investigation of secondary mediators in its pathogenesis. Am J Pathol 122:231–239, 1986Google Scholar
- 11.Hsueh W, Gonzalez-Crussi F, Ischemic bowel necrosis induced by platelet-activating factor: An experimental model. Methods Achiev Exp Pathol 13:208–239, 1988Google Scholar
- 12.Kasuya Y, Masuda Y, Shigenobu K: Possible role of endothelium of the vasodilator response of rat thoracic aorta to platelet activating factor. J Pharmacobiodyn 7:138–142, 1984Google Scholar
- 13.Hsueh W, Gonzalez-Crussi F, Arroyave JL: Release of leukotriene C4 by isolated perfused rat small intestine in response to platelet activating factor. J Clin Invest 78:108–114, 1986Google Scholar
- 14.Hsueh W, Gonzalez-Crussi F, Arroyave JL: Sequential release of leukotrienes and norepinephrine in rat bowel after platelet-activating factor. Gastroenterology 94:1412–1418, 1988Google Scholar
- 15.Snyder DW, Giles RE, Keith RA, Yee YK, Krell RD:In vitro pharmacology of ICI 198,615: A novel, potent and selective peptide leukotriene antagonist. J Pharmacol Exp Ther 243:548–557, 1987Google Scholar
- 16.Cueva JP, Hsueh W: Role of oxygen derived free radicals in platelet activating factor induced bowel necrosis. Gut 29:1207–1212, 1988Google Scholar
- 17.Needleman P, Marshall GR, Johnson EM Jr: Determinants and modification of adrenergic and vascular resistance in the kidney. Am J Physiol 227:665–669, 1974Google Scholar
- 18.Robert A: Protection against mucosal damage: Mechanism of action of eicosanoids.In Advances in Eicosanoid Research. K Hillier (ed). Eicosanoids and the Gastrointestinal Tract. MTP Press Limited, Lancaster, England. 1988, pp 103–110.Google Scholar
- 19.Braquet P, Etienne A, Mencia-Huerta J-M, Clostre F: Effects of the specific platelet-activating factor antagonists, BN 52021 and BN 52063, on various experimental gastrointestinal ulcerations. Eur J Pharmacol 150:269–276, 1988Google Scholar
- 20.Siren A-L, Feuerstein G: Effects of PAF and BN 52021 on cardiac function and regional blood flow in conscious rats. Am J Physiol 257:H23-H32, 1989Google Scholar
- 21.Kubes P, Suzuki M, Granger DN: Platelet-activating factor-induced microvascular dysfunction: Role of adherent leukocytes. Am J Physiol 258:G158-G163, 1990Google Scholar
- 22.Rosam A-C, Wallace JL, Whittle BJR: Potent ulcerogenic actions of platelet activating factor on the stomach. Nature 319:54–56, 1986Google Scholar